CLINICAL STUDIES
Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure
A randomized, double-blind, placebo-controlled clinical trial
Roger M. Mills, MD, FACC*,
Thierry H. LeJemtel, MD ,
Darlene P. Horton, MD ,
Chang-seng Liang, MD, PhD, FACC ,
Roberto Lang, MD, FACC||,
Marc A. Silver, MD, FACC¶,
Charles Lui, MD, FACC#,
Kanu Chatterjee, MD, FACC** on Behalf of the Natrecor Study Group1
* Division of Cardiovascular Medicine, University of Florida, Gainesville, Florida, USA
Division of Cardiology, Albert Einstein College of Medicine, Bronx, New York, USA
Clinical Research Division, Scios Inc., Mountain View, California, USA
Cardiology Unit, University of Rochester Medical Center, Rochester, New York, USA
|| Section of Cardiology, University of Chicago, Chicago, Illinois, USA
¶ Division of Cardiology, Loyola University Medical Center, Maywood, Illinois, USA
# Division of Cardiology, University of Arizona, Tucson, Arizona, USA
** Division of Cardiology, University of California San Francisco, San Francisco, California, USA
Manuscript received September 30, 1998;
revised manuscript received February 24, 1999,
accepted March 31, 1999.
Reprint requests and correspondence: Dr. Roger M. Mills, Desk F-15, Department of Cardiology, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio 44195
OBJECTIVES
The goal of this study was to further define the role of nesiritide (human b-type natriuretic peptide) in the therapy of decompensated heart failure (HF) by assessing the hemodynamic effects of three doses (0.015, 0.03 and 0.06 µg/kg/min) administered by continuous intravenous (IV) infusion over 24 h as compared with placebo.
BACKGROUND
Previous studies have shown beneficial hemodynamic, neurohormonal and renal effects of bolus dose and 6-h infusion administration of nesiritide in HF patients. Longer term safety and efficacy have not been studied.
METHODS
This randomized, double-blind, placebo-controlled multicenter trial enrolled subjects with symptomatic HF and systolic dysfunction (left ventricular ejection fraction  35%). Central hemodynamics were assessed at baseline, during a 24-h IV infusion and for 4 h postinfusion.
RESULTS
One hundred three subjects with New York Heart Association class II (6%), III (61%) or IV (33%) HF were enrolled. Nesiritide produced significant reductions in pulmonary wedge pressure (27% to 39% decrease by 6 h), mean right atrial pressure and systemic vascular resistance, along with significant increases in cardiac index and stroke volume index, with no significant effect on heart rate. Beneficial effects were evident at 1 h and were sustained throughout the 24-h infusion.
CONCLUSIONS
The rapid and sustained beneficial hemodynamic effects of nesiritide observed in this study support its use as a first-line IV therapy for patients with symptomatic decompensated HF.
|
Abbreviations and Acronyms
| | CI | = cardiac index | | hBNP | = human b-type natriuretic peptide | | HF | = heart failure | | IV | = intravenous | | MRAP | = mean right atrial pressure | | PCWP | = pulmonary capillary wedge pressure | | SBP | = systemic systolic blood pressure | | SVR | = systemic vascular resistance |
|
This article has been cited by other articles:
|
|
|
|
 
O. Tsukamoto, M. Fujita, M. Kato, S. Yamazaki, Y. Asano, A. Ogai, H. Okazaki, M. Asai, Y. Nagamachi, N. Maeda, et al.
Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure.
J. Am. Coll. Cardiol.,
June 2, 2009;
53(22):
2070 - 2077.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Simsic, W. T. Mahle, A. Cuadrado, P. M. Kirshbom, and K. O. Maher
Hemodynamic Effects and Safety of Nesiritide in Neonates with Heart Failure
J Intensive Care Med,
November 1, 2008;
23(6):
389 - 395.
[Abstract]
[PDF]
|
|
|
|
|
|
|
E. E. Niederkofler, U. A. Kiernan, J. O'Rear, S. Menon, S. Saghir, A. A. Protter, R. W. Nelson, and U. Schellenberger
Detection of Endogenous B-Type Natriuretic Peptide at Very Low Concentrations in Patients With Heart Failure
Circ Heart Fail,
November 1, 2008;
1(4):
258 - 264.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Burnett Jr and J. Korinek
The Tumultuous Journey of Nesiritide: Past, Present, and Future
Circ Heart Fail,
May 1, 2008;
1(1):
6 - 8.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R J Hillock, C M Frampton, T G Yandle, R W Troughton, J G Lainchbury, and A M Richards
B-type natriuretic peptide infusions in acute myocardial infarction
Heart,
May 1, 2008;
94(5):
617 - 622.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Kazory and E. A. Ross
Contemporary Trends in the Pharmacological and Extracorporeal Management of Heart Failure: A Nephrologic Perspective
Circulation,
February 19, 2008;
117(7):
975 - 983.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. De Luca, A. Mebazaa, G. Filippatos, J. T. Parissis, M. Bohm, A. A. Voors, M. Nieminen, F. Zannad, A. Rhodes, A. El-Banayosy, et al.
Overview of emerging pharmacologic agents for acute heart failure syndromes
Eur J Heart Fail,
February 1, 2008;
10(2):
201 - 213.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Rose and W. R. Giles
Natriuretic peptide C receptor signalling in the heart and vasculature
J. Physiol.,
January 15, 2008;
586(2):
353 - 366.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Belenkie
Nesiritide Administration in Patients With Left Ventricular Dysfunction Undergoing Coronary Artery Bypass Surgery
J. Am. Coll. Cardiol.,
February 13, 2007;
49(6):
727 - 728.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Mentzer Jr, M. C. Oz, R. N. Sladen, A. H. Graeve, R. F. Hebeler Jr, J. M. Luber Jr, N. G. Smedira, and on behalf of the NAPA Investigators
Effects of Perioperative Nesiritide in Patients With Left Ventricular Dysfunction Undergoing Cardiac Surgery: The NAPA Trial
J. Am. Coll. Cardiol.,
February 13, 2007;
49(6):
716 - 726.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. H. Chen and J. C. Burnett Jr
Clinical application of the natriuretic peptides in heart failure
Eur. Heart J. Suppl.,
September 1, 2006;
8(suppl_E):
E18 - E25.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. S. Kesselheim, M. A. Fischer, and J. Avorn
The rise and fall of Natrecor for congestive heart failure: implications for drug policy.
Health Aff.,
July 1, 2006;
25(4):
1095 - 1102.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P.A. Gould, J. D'Agostino, H.G. Schneider, and D.M. Kaye
Influence of atrial fibrillation on cardiac brain natriuretic peptide release during haemodynamic stress in heart failure
Eur J Heart Fail,
May 1, 2006;
8(3):
263 - 269.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Simsic, M. Scheurer, J. D. Tobias, J. Berkenbosch, W. Schechter, F. Madera, S. Weinstein, and R. E. Michler
Perioperative Effects and Safety of Nesiritide Following Cardiac Surgery in Children
J Intensive Care Med,
January 1, 2006;
21(1):
22 - 26.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. B. Bauer and M. A. Randazzo
Nesiritide for outpatient treatment of heart failure
Am. J. Health Syst. Pharm.,
December 15, 2005;
62(24):
2639 - 2642.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. D. Sackner-Bernstein, M. Kowalski, M. Fox, and K. Aaronson
Short-term Risk of Death After Treatment With Nesiritide for Decompensated Heart Failure: A Pooled Analysis of Randomized Controlled Trials
JAMA,
April 20, 2005;
293(15):
1900 - 1905.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Elkayam, D. J. Wang, T. C. Dowling, D. Meadows, T. Ayala, J. Marshall, S. Minshall, N. Greenberg, E. Thattassery, M. L. Fisher, et al.
Letter Regarding Article by Wang et al, "Nesiritide Does Not Improve Renal Function in Patients With Chronic Heart Failure and Worsening Serum Creatinine" * Response
Circulation,
April 12, 2005;
111(14):
e182 - e183.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Nieminen
Pharmacological options for acute heart failure syndromes: current treatments and unmet needs
Eur. Heart J. Suppl.,
April 1, 2005;
7(suppl_B):
B20 - B24.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. D. Sackner-Bernstein, H. A. Skopicki, and K. D. Aaronson
Risk of Worsening Renal Function With Nesiritide in Patients With Acutely Decompensated Heart Failure
Circulation,
March 29, 2005;
111(12):
1487 - 1491.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. M. O'Dell, J. S. Kalus, S. Kucukarslan, and B. Czerska
Nesiritide for secondary pulmonary hypertension in patients with end-stage heart failure
Am. J. Health Syst. Pharm.,
March 15, 2005;
62(6):
606 - 609.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Witteles, K. Matsuda, and M. B. Fowler
B-Type Natriuretic Peptide Is Effective Therapy before Care
Ann Intern Med,
December 7, 2004;
141(11):
895 - 895.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Kawakami, Y. Saito, I. Kishimoto, M. Harada, K. Kuwahara, N. Takahashi, Y. Nakagawa, M. Nakanishi, K. Tanimoto, S. Usami, et al.
Overexpression of Brain Natriuretic Peptide Facilitates Neutrophil Infiltration and Cardiac Matrix Metalloproteinase-9 Expression After Acute Myocardial Infarction
Circulation,
November 23, 2004;
110(21):
3306 - 3312.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Wang, T. C. Dowling, D. Meadows, T. Ayala, J. Marshall, S. Minshall, N. Greenberg, E. Thattassery, M. L. Fisher, K. Rao, et al.
Nesiritide Does Not Improve Renal Function in Patients With Chronic Heart Failure and Worsening Serum Creatinine
Circulation,
September 21, 2004;
110(12):
1620 - 1625.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Patel, J. R. Dietz, A. Owen, G. S. Miguel, M. T. McCormick, D. D. Schocken, and D. L. Vesely
Combined Treatment with Vessel Dilator and Kaliuretic Hormone in Persons with Congestive Heart Failure
Experimental Biology and Medicine,
June 1, 2004;
229(6):
521 - 527.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J DiDomenico, H. Y Park, M. R. Southworth, H. M Eyrich, R. K Lewis, J. M Finley, and G. T Schumock
Guidelines for Acute Decompensated Heart Failure Treatment
Ann. Pharmacother.,
April 1, 2004;
38(4):
649 - 660.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. de Denus, C. Pharand, and D. R. Williamson
Brain Natriuretic Peptide in the Management of Heart Failure: The Versatile Neurohormone
Chest,
February 1, 2004;
125(2):
652 - 668.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. I. McFarlane, N. Winer, and J. R. Sowers
Role of the Natriuretic Peptide System in Cardiorenal Protection
Arch Intern Med,
December 8, 2003;
163(22):
2696 - 2704.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. van der Zander, A. J. H. M. Houben, L. Hofstra, A. A. Kroon, and P. W. de Leeuw
Hemodynamic and renal effects of low-dose brain natriuretic peptide infusion in humans: a randomized, placebo-controlled crossover study
Am J Physiol Heart Circ Physiol,
August 7, 2003;
285(3):
H1206 - H1212.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. D. Michaels, A. Klein, J. A. Madden, and K. Chatterjee
Effects of Intravenous Nesiritide on Human Coronary Vasomotor Regulation and Myocardial Oxygen Uptake
Circulation,
June 3, 2003;
107(21):
2697 - 2701.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Vichiendilokkul, A. Tran, and E. Racine
Nesiritide: A Novel Approach for Acute Heart Failure
Ann. Pharmacother.,
February 1, 2003;
37(2):
247 - 258.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Militello
Role of Nesiritide in Decompensated Heart Failure
Journal of Pharmacy Practice,
August 1, 2002;
15(4):
326 - 333.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. POPPAS and S. ROUNDS
Congestive Heart Failure
Am. J. Respir. Crit. Care Med.,
January 1, 2002;
165(1):
4 - 8.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. L Vesely
Atrial natriuretic peptides in pathophysiological diseases
Cardiovasc Res,
September 1, 2001;
51(4):
647 - 658.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. A. Sagnella
Atrial natriuretic peptide mimetics and vasopeptidase inhibitors
Cardiovasc Res,
August 15, 2001;
51(3):
416 - 428.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W.-G. Forssmann, M. Meyer, and K. Forssmann
The renal urodilatin system: clinical implications
Cardiovasc Res,
August 15, 2001;
51(3):
450 - 462.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Peter Brunner-La Rocca, W. Kiowski, D. Ramsay, and G. Sutsch
Therapeutic benefits of increasing natriuretic peptide levels
Cardiovasc Res,
August 15, 2001;
51(3):
510 - 520.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. P. Brunner-La Rocca, D. M. Kaye, R. L. Woods, J. Hastings, and M. D. Esler
Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects
J. Am. Coll. Cardiol.,
April 1, 2001;
37(5):
1221 - 1227.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. A Sagnella
Practical implications of current natriuretic peptide research
Journal of Renin-Angiotensin-Aldosterone System,
December 1, 2000;
1(4):
304 - 315.
[PDF]
|
|
|
|
|
|
|
W. S. Colucci, U. Elkayam, D. P. Horton, W. T. Abraham, R. C. Bourge, A. D. Johnson, L. E. Wagoner, M. M. Givertz, C.-s. Liang, M. Neibaur, et al.
Intravenous Nesiritide, a Natriuretic Peptide, in the Treatment of Decompensated Congestive Heart Failure
N. Engl. J. Med.,
July 27, 2000;
343(4):
246 - 253.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
